We have located links that may give you full text access.
The role of curcumae rhizoma-sparganii rhizoma medicated serum in epithelial-mesenchymal transition in the triple negative breast cancer: Pharmacological role of CR-SR in the TBNC.
Biomedicine & Pharmacotherapy 2018 March
The aim of this study was to investigate the effect of Curcumae Rhizoma-Sparganii Rhizoma (CR-SR) medicated serum on the changes of epithelial-mesenchymal transition (EMT) in the triple-negative breast cancer (TNBC). The EMT model was developed by using the TNBC MDA-MB-468 cells, which were treated with TGF-β1. The migration and invasion abilities of TGF-β1-treated MDA-MB-468 cells were detected by wound healing assay and transwell assay. Protein expression levels of E-cadherin and vimentin were determined by western blot. CR-SR medicated serum repressed the phenotypic transition in the TGF-β1-induced MDA-MB-468 cells. Moreover, CR-SR medicated serum inhibited TGF-β1-induced cell proliferation, migration and invasion. Besides, CR-SR medicated serum could reduce TGF-β1-induced up-regulation of the phosphorylation levels of Smad3, and reduce the expression of several transcription factors (Snail1, Snail2 and Twist1). CR-SR medicated serum might suppress TGF-β1-induced EMT in TNBC by decreasing the phosphorylated Smad3 (p-Smad3) pathway in vitro.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices 
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app